Loading
Nanoplatforms for Cancer Theranostics / Cancer Research and Treatments · Journal article
Nano-micro Letters · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical study describes design and characterization of a novel pH/laser-responsive manganese–chlorella hydrogel (CMCGel) intended for perioperative pancreatic cancer management. The material showed in vitro tumor suppression (85.81%) and in vivo efficacy (96.01%), plus adhesion durability and amylase leakage reduction in artificial pancreatic fluid, but these are surrogate endpoints in models without human safety or efficacy data.
Preclinical in vitro and in vivo proof-of-concept study. In vitro: cultured cancer cells in acidic microenvironment. In vivo: tumor-bearing animals (model not explicitly named). Artificial pancreatic fluid used as a tissue-mimicking medium.. Intervention: Injectable self-healing hydrogel (CMCGel) composed of manganese ions and carboxymethyl chitosan loaded with chlorella extract, with pH/laser dual-responsive release of active agents..
In vitro tumor suppression rate: 85.81% In vivo tumor suppression rate: 96.01% Adhesion strength at 48 h in artificial pancreatic fluid: 4703.80 ± 50.36 Pa, only 8.17% lower than at 10 min
Biodegradation kinetics, systemic toxicity, and long-term biocompatibility in vivo not reported.
This work presents a novel materials platform with encouraging preclinical results but is far from clinical use. Researchers and companies may pursue further development, but clinicians should not alter pancreatic cancer perioperative practice based on these data; human safety and efficacy studies are needed.
This is a preclinical proof-of-concept study of a novel hydrogel material tested in vitro and in animal models, demonstrating feasibility but lacking human clinical data or comparison to standard therapy.
As stated by the source record.
Quoted from the source exactly as published.
This work presents a novel materials platform with encouraging preclinical results but is far from clinical use. Researchers and companies may pursue further development, but clinicians should not alter pancreatic cancer perioperative practice based on these data; human safety and efficacy studies are needed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Pancreatic cancer faces the challenges of tumor progression and postoperative pancreatic fistula during the perioperative period, which severely affect patient prognosis. In this study, an injectable self-healing multifunctional hydrogel (CMCGel) was developed based on dynamic cross‑linking between manganese ions (Mn 2+ ) and carboxymethyl chitosan loaded with chlorella extract (CE). This platform implements an integrated “Remove – Remodel – Repair” (3R) strategy for comprehensive perioperative management. CMCGel exhibits distinctive pH/laser dual-responsive behavior: In the acidic tumor microenvironment, the accelerated release of CE and Mn 2+ enhances photodynamic therapy and chemodynamic therapy (CDT). This combination, activated by laser and gated by endogenous pH, achieves remarkable tumor suppression rates of 85.81% in vitro and 96.01% in vivo. As pH normalizes, Mn 2+ shifts from CDT to activate the cyclic GMP-AMP synthase stimulator of interferon genes (cGAS-STING) pathway, remodeling the immune microenvironment. Crucially, CMCGel’s adhesion strength in artificial pancreatic fluid at 48 h was 4703.80 ± 50.36 Pa, only 8.17% lower than that at 10 min. This enzyme-resistant property enables durable mechanical sealing at the fistula site, reducing amylase leakage by 55.71% and creating favorable conditions for tissue repair. By integrating pH/laser-triggered combination therapy, immunomodulation, and enzyme-resistant barrier functionality into a single platform, CMCGel presents a clinically promising strategy for perioperative management of pancreatic cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.